ART adherence changes among patients in community substance use treatment: a preliminary analysis from MACH14 by Rosen, Marc I et al.
 
ART adherence changes among patients in community
substance use treatment: a preliminary analysis from MACH14
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Rosen, Marc I, Anne C Black, Julia H Arnsten, Jane M Simoni,
Glann J Wagner, Kathleen Goggin, Robert H Remien, et al.
2012. Art adherence changes among patients in community
substance use treatment: a preliminary analysis from MACH14.
AIDS Research and Therapy 9:30.
Published Version doi:10.1186/1742-6405-9-30
Accessed February 19, 2015 11:53:58 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10581396
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-
of-use#LAASHORT REPORT Open Access
ART adherence changes among patients in
community substance use treatment:
a preliminary analysis from MACH14
Marc I Rosen
1*, Anne C Black
1, Julia H Arnsten
2, Jane M Simoni
3, Glann J Wagner
4, Kathleen Goggin
5,
Robert H Remien
6, Carol E Golin
7, Yan Wang
8, David Bangsberg
9 and Honghu H Liu
10
for the MACH14 Study Group
Abstract
Background: Opiate substitution treatment has been associated with better adherence to lifesaving antiretroviral
medications, but the impact of other substance abuse treatment on adherence is unknown.
Findings: In this study, 215 patients who had been in adherence-focused research studies provided
electronically-measured adherence data and a measure of whether the patient had recently been in substance
abuse treatment. Recent engagement in substance abuse treatment was independently associated with
significantly higher adherence, after covarying for recent substance use and other factors potentially affecting
adherence.
Conclusions: The findings suggest that substance abuse treatment is associated with better adherence.
Potential mechanisms by which substance abuse treatment improves adherence, such as more stability or more
future-orientation, require further study.
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Background
There are considerable data suggesting that current sub-
stance abuse is associated with both worse adherence to
antiretroviral medications and worse attendance at HIV
treatment visits [1]. HIV-positive patients who use drugs
or alcohol may be referred to standard substance abuse
treatment with the hope that medication adherence will
improve with abstinence.
However, among substance abuse treatments, only opi-
ate substitution treatment has consistently been asso-
ciated with better adherence, as summarized in a 2008
meta-analysis [2]. Both buprenorphine [3,4] and metha-
done maintenance [5,6] have been consistently associated
with better adherence. Patients who received both opiate
substitution treatment and directly observed therapy
have shown even better adherence over time than with
those receiving opiate substitution alone [7,8].
It is not known whether enrollment in substance abuse
treatments other than opioid substitution is associated
with better adherence. In this study, we used data pooled
from two clinical trials of adherence-focused interven-
tions to test the hypotheses that HIV-infected people
who had recently been in substance abuse treatment
would have better antiretroviral adherence, and better
adherence over time, than those who had not had recent
substance abuse treatment.
Methods
Overview and sampling
The data were drawn from two of the sixteen studies in
the MACH14 cohort [9]. The MACH 14 cohort is a
dataset pooled from 16 studies conducted at 14 sites
across 12 states. Each study in MACH14 used electronic
data monitoring (EDM) pillcaps to objectively measure
participants’ adherence to antiretroviral medication. The
* Correspondence: Marc.Rosen@Yale.edu
1Department of Psychiatry, Yale University School of Medicine, New Haven,
CT; VA Connecticut Healthcare System, West Haven, CT 06516, USA
Full list of author information is available at the end of the article
© 2012 Rosen et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Rosen et al. AIDS Research and Therapy 2012, 9:30
http://www.aidsrestherapy.com/content/9/1/30focus of this study was on non-methadone substance
abuse treatment so studies conducted in methadone
maintenance programs were not considered in this ana-
lysis. From the 1579 participants in the MACH14 data-
set, we identified 215 from two studies based outside
methadone clinics [10,11] because only these two stud-
ies’ participants had both EDM and substance abuse
treatment status data. Written informed consent was
obtained for participation in the parent studies, and the
Yale Institutional Review Board approved the secondary
analyses.
Patients were asked about engagement in substance
abuse treatment and use of specific substances for vary-
ing preceding timeframes: one of the two studies (n=47)
asked about participation in substance abuse treatment
during the past 90 days and use of specific substances
over the past 30 days, while the other study (n = 168)
asked about treatment over the past 30 days and sub-
stance use over past 14 days. To aggregate substance use
data across studies, variables representing use of specific
substances were defined as the proportion of days within
the asked-about timeframe the person had used each of
several substances.
This analysis used data collected at the first time-
point at which participants had EDM data for the pre-
ceding four weeks, had also been asked about being re-
cently enrolled in substance abuse treatment, and were
not enrolled in a methadone-clinic-based study. To es-
timate the effect of substance abuse treatment on ad-
herence, adherence was calculated for the four weeks
up to and including the date recent substance abuse
treatment enrollment was assessed, as well as for the
four weeks after the substance abuse treatment deter-
mination. Adherence in each week was calculated by
dividing the weekly number of doses taken by the
weekly number of prescribed doses for each medica-
tion, with adherence to each medication capped at
100%. Adherence for a patient on multiple anti-
retrovirals was calculated by averaging across pre-
scribed medications.
Data analysis
The effects of substance abuse treatment on adherence
were determined in multivariate analyses that included a
grouping variable denoting whether the patient was en-
rolled in substance abuse treatment and a variable
reflecting substance abuse treatment over time. The ana-
lyses were conducted controlling for sociodemographic
characteristics that might differ between patients in, and
not in, substance abuse treatment. To control for the
anticipated finding that patients in substance abuse
treatment would have more active drug use than a refer-
ence group including people who had never had signifi-
cant substance use, analyses included a measure
representing the largest proportion of days during which
participants had used either cocaine, opiates, or stimu-
lants. Cannabis use was not included in this measure of
illicit drug use because in a separate analysis of the
MACH14 dataset [12] and in an earlier study [13] recent
cannabis use was not associated with worse adherence.
Analyses were run with SAS 9.2. The model included
random effects for intercept and slope as this model had
better fit to the data than models with fixed effects only.
Results
Baseline characteristics
Overall, the sample was 65.7% male, and was composed
of 49.3% African American, 2.8% Hispanic, and 19.5%
Caucasian participants. Only 40.1% were employed.
Altogether, 39.5% were men who have sex with men
(MSM). Mean CD4+ count was 232.2 (+/− 206.9) and
8.5% of the 199 patients with viral load results available
had undetectable HIV viral loads (<400); these measures
of HIV disease did not differ between those in and those
not in substance abuse treatment. Mean adherence dur-
ing the first week was 82% (+/− 30%) overall, with 57.2%
(123/215) having 100% adherence, and 12.6% (27/215)
having adherence over 90% but less than 100%.
Of the 215 participants, 13 had recently been in sub-
stance abuse treatment— one had been in residential
treatment and the rest did not specify the type of treat-
ment attended. Table 1 compares those in substance
abuse treatment to those not in it; those in treatment
were less likely to be African American (Fisher’s Exact
Test =.04), and had used alcohol on a lower percentage
of days (t=5.9, p<.0001). Only one of the thirteen
patients in substance abuse treatment had used alcohol
recently and none had used other substances, whereas
there were substantial rates of recent use of several sub-
stances among those out of treatment.
Multivariate analysis
The multivariate analysis estimated the effects of socio-
demographic measures (age, gender, race/ethnicity,
MSM-status, employment), time in weeks, and max-
imum proportion days reported using an illicit drug
(Table 2). As expected, adherence was slightly and sig-
nificantly worse over time (estimate =−.02, p=.002).
Being in substance abuse treatment was associated with
better overall adherence (estimate =0.09, p= .05). The
week by treatment interaction was not statistically sig-
nificant and was removed from the model; substance
abuse treatment status did not significantly change ad-
herence over time.
Discussion
Substance use treatment may improve adherence by sev-
eral mechanisms. Although the analyses controlled for
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sures of substance use understated the impact of sub-
stance abuse treatment on substance abuse and that it is
in fact abstinence that facilitates adherence. In one of
the few randomized controlled studies of HIV-positive
drug users in which abstinence was the target outcome,
there was a trend towards a significant correlation
between consecutive weeks of toxicology-tested abstin-
ence during the intervention and reductions in viral load
[14]. There is also evidence from a naturalistic longitu-
dinal cohort study that attendance at HIV treatment, a
sine qua non for adherence, appears to improve with
newly-achieved abstinence [1].
Substance abuse treatment might improve adherence
by mechanisms other than facilitating abstinence from
using drugs. Substance abuse treatment typically
involves case management [15] to address the unstable
housing characteristic of drug users [16]. Stable housing
arrangements during substance abuse treatment would
be expected to foster adherence, in that stable routines
have been associated with better adherence [17]. Sub-
stance abuse treatment also focuses patients on future
goals, an orientation that has been described as fostering
adherence [18], and substance abuse treatment can in-
volve re-arranging social networks in ways that also
might foster better adherence [19].
It is possible that enrollment in substance abuse treat-
ment reflects a lurking un-measured variable associated
with both being in substance abuse treatment and better
adherence. The finding of better adherence among
people in substance abuse treatment was not buttressed
by finding better adherence over time among patients in
treatment. However, it might have been difficult to
Table 1 Baseline group characteristics
In Substance Abuse Treatment NOT In Substance Abuse Treatment Test Statistic df p
N mean +/− sd or % N mean +/− sd or %
Demographic Variables 13 202
Age 13 38.8+/−8.0 187 40.3+/−8.2 t=−0.63 198 NS
Gender (Male) 9 69.2% 131 65.5% = 0.08 1 NS
Ethnicity Fisher Exact 0.04
Caucasian 5 38.5% 37 18.3%
African American 2 15.4% 104 51.5%
Hispanic 0 0% 6 3.0%
Employed 2 18.2% 65 41.7% Fisher Exact NS
MSM 5 55.6% 80 63.5% Fisher Exact NS
HIV Markers
Mean CD4+ 13 295.4+/−202.6 186 227.8+/−207.0 t=1.14 197 NS
Non-Detectable (%) 12 92.3% 170 91.4% Fisher Exact NS
Substance Use Variables
Proportion Days Used Alcohol 13 0.0055+/−0.020 188 0.088+/−0.1775 t=−5.86 173.0 <.0001
% Recent Alcohol Use 1 7.7% 78 38.6% Fisher Exact 0.034
% Recent Cannabis 0 21 13.4%
% Recent Cocaine 0 7 3.5%
% Recent Heroin 0 2 0.99%
% Recent Stimulants 0 9 4.5%
% Used Any Illicit Drug 0 17 8.4%
Table 2 Impact of Predictors on Antiretroviral Adherence
[1]
Effect Estimate Pr >|t|
Intercept 0.82 <.0001
Week −0.02 0.0022
Recent Substance Abuse Treatment (yes/no) 0.09 0.0471
Male 0.08 0.0216
African American(Caucasian is Reference) 0.05 NS
Hispanic 0.07 NS
Other Race 0.05 NS
Illicit Drug Use (largest proportion of days
reported use of illicit drug other than cannabis)
−0.13 NS
Man who has Sex with Men 0.02 NS
Employed −0.03 NS
1-Adherence was proportion of prescribed doses taken during an eight week
period comprising each of 4 weeks before and 4 weeks after substance abuse
treatment status was inquired about.
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treatment because the data did not specify when patients
were entering, continuing, or finishing substance abuse
treatment.
There are several other caveats in interpreting these
findings. Substance abuse was measured by self-report,
and it is possible that substance abuse was dispropor-
tionately under-reported by people out of substance
abuse treatment, thus exaggerating the impact of sub-
stance abuse treatment on adherence. The type of sub-
stance abuse treatment was not specified and the
findings may not apply to all types of substance abuse
treatment. Finally, the sample size was modest, and the
number of participants in substance abuse treatment
was small. It is noteworthy that although adherence
decreased on average over time, the course of adherence
varied significantly by person. Further analyses should
test variables that may account for individual differences
in adherence over time.
These findings lend some support to the clinical prac-
tice of addressing substance use in an effort to improve
adherence. The crucial next step is to develop and pro-
spectively test substance abuse-focused interventions for
patients with both substance abuse and adherence
problems.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MR designed the analyses and drafted the manuscript. All the authors read
and approved the final manuscript. All the authors except ACB and YW
contributed patient data to the MACH 14 dataset. ACB helped design the
analyses, and the aggregated dataset from which they were drawn. YW and
HHL conducted the statistical analyses.
Acknowledgements
This research was supported by the multi-site adherence collaboration in HIV
(MACH14) grant R01MH078773 from the National Institute of Mental Health
(NIMH), Office on AIDS. The original grants of individual participating studies
are: R01DA11869, MH54907, R01 NR04749, R01 NR04749, MH68197, R01
DA13826, K23MH01862, MH01584, R01 AI41413, R01 MH61173, NIH/ NIAID
AI38858, AI069419, K02 DA017277, R01 DA15215, NIMH P01 MH49548,
MH58986, RO1MH61695, CC99-SD003, CC02-SD-003 and R01 DA015679. We
would like to thank all the patients who participated in each of the
individual studies. The content of the paper is solely the responsibility of the
authors and does not necessarily represent the official views of the National
Institutes of Health.
Author details
1Department of Psychiatry, Yale University School of Medicine, New Haven,
CT; VA Connecticut Healthcare System, West Haven, CT 06516, USA.
2Departments of Medicine and Psychiatry & Behavioral Sciences, Albert
Einstein College of Medicine and Montefiore Medical Center, Einstein/
Montefiore Center for AIDS Research, Bronx, NY 10467, USA.
3Department of
Psychology, University of Washington, Seattle, WA 98195, USA.
4Rand
Corporation Health Unit, Santa Monica, CA 90407, USA.
5Department of
Psychology, University of Missouri-Kansas City, Kansas City, MO 64110, USA.
6HIV Center for Clinical and Behavioral Studies, NY State Psychiatric Institute
and Columbia University, New York, NY 10032, USA.
7UNC Departments of
Medicine and Health Behavior & Health Education; UNC Center for AIDS
Research, Cecil G. Sheps Center for Health Services Research, Chapel Hill, NC
27599, USA.
8Department of Biostatistics, University of California Los Angeles
(UCLA), Los Angeles, CA 90095, USA.
9Mbarara University of Science and
Technology; Harvard Medical School; Ragon Institute of MGH, Harvard, and
MIT; Division of Global Health Equity at Brigham’s and Women’s Hospital;
Massachusetts General Hospital Center for Global Health, Boston, MA 02114,
USA.
10Schools of Dentistry, Medicine and Public Health, University of
California Los Angeles (UCLA), Los Angeles, CA 90095, USA.
Received: 29 June 2012 Accepted: 28 September 2012
Published: 11 October 2012
References
1. Sohler NL, Wong MD, Cunningham WE, Cabral H, Drainoni M-L,
Cunningham CO: Type and pattern of illicit drug use and access to
health care services for HIV-infected people. AIDS Patient Care STDS 2007,
21(Suppl 1):S68–S76.
2. Malta M, Magnanini M, Strathdee S, Bastos F: Adherence to Antiretroviral
Therapy Among HIV-Infected Drug Users: A Meta-Analysis. AIDS Behav
2010, 14:731–747.
3. Altice FL, Bruce RD, Lucas GM, Lum PJ, Korthuis PT, Flanigan TP,
Cunningham CO, Sullivan LE, Vergara-Rodriguez P, Fiellin DA, Cajina A,
Botsko M, Nandi V, Gourevitch MN, Finkelstein R, Collaborative B: HIV
treatment outcomes among HIV-infected, opioid-dependent patients
receiving buprenorphine/naloxone treatment within HIV clinical care
settings: results from a multisite study. JAIDS 2011, 56(Suppl 1):S22–S32.
4. Moatti JP, Carrieri MP, Spire B, Gastaut JA, Cassuto JP, Moreau J: Adherence
to HAART in French HIV-infected injecting drug users: the contribution
of buprenorphine drug maintenance treatment. AIDS 2000, 14:151–155.
5. Uhlmann S, Milloy MJ, Kerr T, Zhang R, Guillemi S, Marsh D, Hogg RS,
Montaner JSG, Wood E: Methadone maintenance therapy promotes
initiation of antiretroviral therapy among injection drug users. Addiction
2010, 105:907–913.
6. Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Hogg RS, Montaner
JSG: Antiretroviral adherence and HIV treatment outcomes among HIV/
HCV co-infected injection drug users: The role of methadone
maintenance therapy. Drug Alcohol Depend 2006, 84:188–194.
7. Altice FL, Maru DS-R, Bruce RD, Springer SA, Friedland GH: Superiority of
directly administered antiretroviral therapy over self-administered
therapy among HIV-infected drug users: a prospective, randomized,
controlled trial. Clin Infect Dis 2007, 45:770–778.
8. Berg KM, Litwin A, Li X, Heo M, Arnsten JH: Directly observed antiretroviral
therapy improves adherence and viral load in drug users attending
methadone maintenance clinics: A randomized controlled trial.
Drug Alcohol Depend 2011, 113:192–199.
9. Liu H, Wilson IB, Goggin K, Reynolds NR, Simoni JM, Golin CE, Rosen MI,
Gross R, Wagner G, Schneiderman N, Remien RH, Erlen JA, Arnsten JH,
Bangsberg DR, or the MACH14 Group MACH14: A Multi-site Collaboration
on ART Adherence among 14 Institutions. AIDS Behav, in press.
10. Wagner GJ, Kanouse DE, Golinelli D, Miller LG, Daar ES, Witt MD,
Diamond C, Tilles JG, Kemper CA, Larsen R, Goicoechea M, Haubrich RH:
Cognitive-behavioral intervention to enhance adherence to
antiretroviral therapy: a randomized controlled trial (CCTG 578).
AIDS 2006, 20:1295–1302.
11. Kushel MB, Colfax G, Ragland K, Heineman A, Palacio H, Bangsberg DR: Case
management is associated with improved antiretroviral adherence and
CD4(+) cell counts in homeless and marginally housed individuals with
HIV infection. Clin Infect Dis 2006, 43:234–242.
12. Rosen MI, Black AC, Arnsten JH, Goggin K, Remien RH, Simoni JM, Golin CE,
Bangsberg DR, Liu H: Association Between Use of Specific Drugs and
Antiretroviral Adherence. Findings from MACH 14. AIDS Behav 2012,
doi:10.1007/s10461-011-0124-7.
13. De Jong BC, Prentiss D, McFarland W, MAchekano R, Israelski DM: Marijuana
use and its association with adherence to antiretroviral therapy among
HIV-infected persons with moderate to severe nausea. J Acquir Immune
Defic Syndr 2005, 38:43–46.
14. Petry NM, Weinstock J, Alessi SM, Lewis MW, Dieckhaus K: Group-based
randomized trial of contigencies for health and abstinence in HIV
patients. J Consult Clin Psychol 2010, 78:89–97.
15. Carroll KM, National Institute of Drug Abuse Therapy Manuals for Drug
Addiction Manual 1: A Cognitive-Behavioral Approach. Treating Drug
Addiction 1998.
Rosen et al. AIDS Research and Therapy 2012, 9:30 Page 4 of 5
http://www.aidsrestherapy.com/content/9/1/3016. Demas P, Schoenbaum EE, Wills TA, Doll LS, Klein RS: Stress, coping, and
attitudes toward HIV treatment in injecting drug users: a qualitative
study. AIDS Educ Prev 1995, 7:429–442.
17. Ryan GW, Wagner GJ: Pill taking 'routinization': a critical factor to
understanding episodic medication adherence. AIDS Care 2003,
15:795–806.
18. Remien RH, Hirky AE, Johnson MO, Weinhardt LS, Whittier D, Le GM:
Adherence to Medication Treatment: A Qualitative Study of Facilitators
and Barriers Among a Diverse Sample of HIV+ Men and Women in Four
U.S. Cities. AIDS Behav 2003, 7:61–72.
19. Rosen MI, Rigsby MO, Dieckhaus KD, Cramer JA: Effects of illicit drug use
on adherence to prescribed antiretroviral medication. Am J Addict 2003,
12:455–458.
doi:10.1186/1742-6405-9-30
Cite this article as: Rosen et al.: ART adherence changes among patients
in community substance use treatment: a preliminary analysis from
MACH14. AIDS Research and Therapy 2012 9:30.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Rosen et al. AIDS Research and Therapy 2012, 9:30 Page 5 of 5
http://www.aidsrestherapy.com/content/9/1/30